A potential HIV vaccine that recently failed a clinical trial in the United States may increase some people's chance of catching the virus that causes AIDS.
Top government and drug industry scientists are currently reviewing data from the trial, which unexpectedly found more HIV infections among study participants who had previously been exposed to a common virus called adenovirus, The Washington Times reported Monday.
"We're trying very hard to understand the data more fully and completely," says Nalini Saligram, a spokeswoman for Merck, co-sponsor of the STEP vaccine trial.
Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Disease, called the trial results "both disappointing and puzzling."
The trial involved 3,000 participants between the ages of 18 and 45 who were at risk of HIV infection based on their behavior.
It ended in September after researchers determined the vaccine failed to decrease either the chance of HIV infection or the amount of virus in people who became infected while taking it.
Copyright 2007 by United Press International
Related stories:
NIAID will not move forward with the PAVE 100 HIV Vaccine Trial
After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100.
Researchers: Program discourages HIV transmission in Russia
(Boston)-Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found that sexual behavior counseling during drug addiction treatment should be considered an important component among Russian substance-dependent individuals, in order to decrease risky sexual behavior in the HIV at-risk population. This study appears in the journal
Addiction.
New HIV browser gives researchers access to valuable data from vaccine trials
A new HIV data browser developed by the University of California, Santa Cruz, and the nonprofit organization Global Solutions for Infectious Diseases (GSID) will give researchers access to a wealth of data collected during clinical trials of an AIDS vaccine. Although the vaccine did not succeed in preventing infections, the clinical trial generated a huge amount of valuable data for researchers studying how the virus evolves and causes new infections.
Study finds unique HIV vaccine formula elicits strong immune responses
Today, Advanced BioScience Laboratories, Inc. and the University of Massachusetts Medical School report that their unique HIV vaccine formulation was effective in eliciting strong and balanced immune responses in healthy human volunteers.
HIV infection stems from few viruses
A new study reveals the genetic identity of human immunodeficiency virus (HIV), the version responsible for sexual transmission, in unprecedented detail.
Clinical trial will test new HIV/AIDS vaccine
A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Women’s Hospital (BWH). This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world.
Experimental HIV vaccine gets a boost from ’70s-era discovery
Although science is known for being a forward-looking field, researchers have found that they can often benefit from a glance over their shoulders. By combining an experimental AIDS vaccine with a long-neglected molecule called poly-IC, Rockefeller University scientists discovered that they were able to significantly improve its effectiveness. Their new, bolstered vaccine not only stimulated the production of HIV-attacking immune cells in mice, but also allowed the rodents to maintain immunity over a significantly longer period of time.
The 'MIP-MAP' game: Indian bug is the ancestor of Crohn's disease pathogen
An Indian team of researchers led by Seyed E. Hasnain of the Institute of Life Sciences (ILS), University of Hyderabad, India has found that a seemingly unknown mycobacterial organism Mycobacterium indicus pranii (MIP) could be the earliest ancestor of the 'generalist' branch of mycobacterial pathogens.